Published in J Histochem Cytochem on May 26, 2009
MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J Am Soc Nephrol (2012) 2.26
Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner. Br J Pharmacol (2011) 0.91
Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors. J Histochem Cytochem (2012) 0.89
Hypothalamic prolyl endopeptidase (PREP) regulates pancreatic insulin and glucagon secretion in mice. Proc Natl Acad Sci U S A (2014) 0.85
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis. J Neuroinflammation (2010) 0.81
Dysregulated bile acid synthesis, metabolism and excretion in a high fat-cholesterol diet-induced fibrotic steatohepatitis in rats. Dig Dis Sci (2013) 0.81
Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase. Neoplasia (2015) 0.81
Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction. J Biol Chem (2015) 0.79
Comparative analysis of the substrate preferences of two post-proline cleaving endopeptidases, prolyl oligopeptidase and fibroblast activation protein α. FEBS Lett (2012) 0.79
The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patients. J Neuroinflammation (2015) 0.77
Prolyl oligopeptidase attenuates hepatic stellate cell activation through induction of Smad7 and PPAR-γ. Exp Ther Med (2017) 0.75
Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins? Front Aging Neurosci (2017) 0.75
Prolyl Oligopeptidase Inhibition Attenuates Steatosis in the L02 Human Liver Cell Line. PLoS One (2016) 0.75
Localization and subcellular distribution of prolyl oligopeptidase in the mouse placenta. J Mol Histol (2011) 0.75
A synaptic model of memory: long-term potentiation in the hippocampus. Nature (1993) 29.13
Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A (2002) 25.47
Analysis and prediction of leucine-rich nuclear export signals. Protein Eng Des Sel (2004) 5.15
MEROPS: the peptidase database. Nucleic Acids Res (2007) 4.32
GAP43, MARCKS, and CAP23 modulate PI(4,5)P(2) at plasmalemmal rafts, and regulate cell cortex actin dynamics through a common mechanism. J Cell Biol (2000) 3.46
Prolyl cis-trans isomerization as a molecular timer. Nat Chem Biol (2007) 3.45
Families of serine peptidases. Methods Enzymol (1994) 2.94
Microstructure of the neocortex: comparative aspects. J Neurocytol (2003) 2.58
A common mechanism of action for three mood-stabilizing drugs. Nature (2002) 2.58
Parvalbumin, somatostatin and cholecystokinin as chemical markers for specific GABAergic interneuron types in the rat frontal cortex. J Neurocytol (2003) 2.56
The cerebellum and the adaptive coordination of movement. Annu Rev Neurosci (1992) 2.22
Effects of environmental enrichment on gene expression in the brain. Proc Natl Acad Sci U S A (2000) 2.13
Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. Cell (1998) 2.08
Global impact of oncogenic Src on a phosphotyrosine proteome. J Proteome Res (2008) 1.94
The effects of aging on gene expression in the hypothalamus and cortex of mice. Proc Natl Acad Sci U S A (2001) 1.72
Substance p. Int J Biochem Cell Biol (2001) 1.70
Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat. J Comp Neurol (1994) 1.59
Proline specific peptidases. Biochim Biophys Acta (1997) 1.54
Neuropeptides: opportunities for drug discovery. Lancet Neurol (2003) 1.41
On the role of prolyl oligopeptidase in health and disease. Neuropeptides (2006) 1.39
B-50, the growth associated protein-43: modulation of cell morphology and communication in the nervous system. Prog Neurobiol (1997) 1.35
The biology of pro-thyrotropin-releasing hormone-derived peptides. Endocr Rev (1999) 1.26
Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension (2004) 1.21
Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect. J Pharmacobiodyn (1987) 1.18
Thyrotropin-releasing hormone receptors -- similarities and differences. J Mol Endocrinol (2003) 1.15
Induction of long-term depression and rebound potentiation by inositol trisphosphate in cerebellar Purkinje neurons. Proc Natl Acad Sci U S A (1997) 1.13
Lithium therapy and signal transduction. Trends Pharmacol Sci (2000) 1.10
Vasopressin: a new target for the treatment of heart failure. Am Heart J (2003) 1.10
Prolyl oligopeptidases. Methods Enzymol (1994) 1.09
Enhanced hippocampal CA1 LTP but normal spatial learning in inositol 1,4,5-trisphosphate 3-kinase(A)-deficient mice. Learn Mem (1999) 1.09
S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. CNS Drug Rev (2002) 1.08
Cortical-area specific block of genetically determined absence seizures by ethosuximide. Neuroscience (2004) 1.08
Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem Cell Biol (2008) 1.07
Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur J Clin Chem Clin Biochem (1996) 1.05
Search for a common mechanism of mood stabilizers. Biochem Pharmacol (2003) 1.02
Leucylglycinamide released from oxytocin by human uterine enzyme. Science (1971) 1.00
Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur J Biochem (2002) 1.00
Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug News Perspect (2007) 0.99
Distribution of putative neurotransmitters in the neocortex. Neuroscience (1979) 0.97
Suggested functions for prolyl oligopeptidase: a puzzling paradox. Clin Chim Acta (2006) 0.97
Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J Neurochem (2005) 0.94
Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides (2000) 0.94
Long-term potentiation activates the GAP-43 promoter: selective participation of hippocampal mossy cells. Proc Natl Acad Sci U S A (1997) 0.94
Brain prolyl endopeptidase expression in aging, APP transgenic mice and Alzheimer's disease. Neurochem Res (2005) 0.93
Overexpression of the angiogenic tetrapeptide AcSDKP in human malignant tumors. Anticancer Res (2008) 0.93
Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem (2003) 0.93
Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein. Peptides (2008) 0.93
Co-expression of neuropeptides in the cat's striatum: an immunohistochemical study of substance P, dynorphin B and enkephalin. Neuroscience (1990) 0.92
Cloning and sequence analysis of the gene encoding human lymphocyte prolyl endopeptidase. Gene (1994) 0.92
Behavioral neuroendocrinology of vasotocin and vasopressin and the sensorimotor processing hypothesis. Front Neuroendocrinol (2002) 0.92
Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. J Comp Neurol (2008) 0.92
Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol Cell Neurosci (2009) 0.92
Evolutionary relationships of the prolyl oligopeptidase family enzymes. Eur J Biochem (2004) 0.92
Concerted structural changes in the peptidase and the propeller domains of prolyl oligopeptidase are required for substrate binding. J Mol Biol (2004) 0.92
Temporal differences in the phosphorylation state of pre- and postsynaptic protein kinase C substrates B-50/GAP-43 and neurogranin during long-term potentiation. J Biol Chem (1995) 0.92
Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis. Biochem Med Metab Biol (1991) 0.91
Involvement of IP3 receptors in LTP and LTD induction in guinea pig hippocampal CA1 neurons. Learn Mem (2005) 0.91
Molecular cloning and characterization of prolyl endopeptidase from human T cells. J Biochem (1994) 0.91
Partial purification and characterization of post-proline cleaving enzyme: enzymatic inactivation of neurohypophyseal hormones by kidney preparations of various species. Biochim Biophys Acta (1976) 0.91
Purification and characterization of a novel membrane-bound form of prolyl endopeptidase from bovine brain. Int J Biochem Cell Biol (1996) 0.90
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. Clin Chim Acta (1996) 0.90
Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain. J Neuroendocrinol (2005) 0.90
Two peptidase activities decrease in treated bipolar disorder not schizophrenic patients. Bipolar Disord (2004) 0.90
A cavity with an appropriate size is the basis of the PPIase activity. Protein Eng Des Sel (2008) 0.89
Identification and localisation of a synaptosomal membrane prolyl endopeptidase from bovine brain. Eur J Biochem (1995) 0.89
JTP-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer. J Pharmacol Exp Ther (1995) 0.88
Distribution and ontogeny of thyrotropin-releasing hormone degrading enzymes in rats. Am J Physiol (1990) 0.88
Prevention of amyloid-like deposition by a selective prolyl endopeptidase inhibitor, Y-29794, in senescence-accelerated mouse. J Pharmacol Exp Ther (1997) 0.88
Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and on cholinergic and peptidergic neurons in rats with ibotenate-induced lesions of the nucleus basalis magnocellularis. Behav Brain Res (1999) 0.88
cDNA cloning of mouse prolyl endopeptidase and its involvement in DNA synthesis by Swiss 3T3 cells. J Biochem (1998) 0.87
Localization of the mRNA encoding prolyl endopeptidase in the rat brain and pituitary. J Comp Neurol (2004) 0.87
Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on prolyl endopeptidase activity and substance P- and arginine-vasopressin-like immunoreactivity in the brains of aged rats. J Neurochem (1995) 0.87
Ontogeny of prolyl endopeptidase and pyroglutamyl peptidase I in rat tissues. Regul Pept (2006) 0.87
Distribution of immunoreactive prolyl oligopeptidase in human and rat brain. Neurochem Res (2007) 0.87
Characterization of membrane-bound prolyl endopeptidase from brain. FEBS J (2008) 0.87
Subcellular distribution of prolyl endopeptidase and cation-sensitive neutral endopeptidase in rabbit brain. J Neurochem (1982) 0.87
Expression and traffic of cellular prolyl oligopeptidase are regulated during cerebellar granule cell differentiation, maturation, and aging. Neuroscience (2008) 0.87
Pharmacogenetics in model systems: defining a common mechanism of action for mood stabilisers. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.86
Distribution of post-proline cleaving enzyme in human brain and the peripheral tissues. Mol Cell Biochem (1980) 0.85
Cellular and subcellular distribution of substance P receptor immunoreactivity in the dorsal vagal complex of the rat and cat: a light and electron microscope study. J Comp Neurol (1998) 0.85
How can the mood stabilizer VPA limit both mania and depression? Mol Cell Neurosci (2005) 0.85
Co-localization of GABA with other neuroactive substances in the basal ganglia. Prog Brain Res (2007) 0.85
Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats. Basic Clin Pharmacol Toxicol (2007) 0.85
Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. Pharmacol Biochem Behav (1997) 0.84
Distribution of prolyl endopeptidase activities in rat and human brain. Neurochem Int (2002) 0.84
Spindle-like thalamocortical synchronization in a rat brain slice preparation. J Neurophysiol (2000) 0.84
Expression and localization of prolyl oligopeptidase in mouse testis and its possible involvement in sperm motility. Zoolog Sci (2002) 0.84
Specific inhibitor for prolyl endopeptidase suppresses the generation of amyloid beta protein in NG108-15 cells. Biochem Biophys Res Commun (1997) 0.83
The role of neuropeptides in learning: focus on the neurokinin substance P. Behav Brain Res (1995) 0.83
Brain peptidases: their possible neuronal and glial localization. Brain Res (1984) 0.83
Neurokinin-1 and neurokinin-3 receptors in primate substantia nigra. Neurosci Res (2006) 0.83
Spatial association of prolyl oligopeptidase, inositol 1,4,5-triphosphate type 1 receptor, substance P and its neurokinin-1 receptor in the rat brain: an immunohistochemical colocalization study. Neuroscience (2008) 0.82
Prolyl endopeptidase is revealed following SILAC analysis to be a novel mediator of human microglial and THP-1 cell neurotoxicity. Glia (2008) 0.82
A prolyl endopeptidase of Sarcophaga peregrina (flesh fly): its purification and suggestion for its participation in the differentiation of the imaginal discs. J Biochem (1994) 0.82
Search for substrates for prolyl oligopeptidase in porcine brain. Peptides (2005) 0.82
Pentylenetetrazol-induced seizures affect the levels of prolyl oligopeptidase, thimet oligopeptidase and glial proteins in rat brain regions, and attenuation by MK-801 pretreatment. Neurochem Int (2005) 0.81
Thyrotropin-releasing hormone enhances excitatory postsynaptic potentials in neocortical neurons of the rat in vitro. Brain Res (1994) 0.81
Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol (2008) 0.81
Structure and localization of the mouse prolyl oligopeptidase gene. J Biol Chem (1999) 0.81
Regulation of prolyl oligopeptidase activity in regenerating rat liver. Biochim Biophys Acta (1994) 0.81
Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci (2007) 1.75
Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A (2005) 1.67
Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology (2007) 1.64
Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp Neurol (2010) 1.59
Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci (2002) 1.51
Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J Biol Chem (2002) 1.31
Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J Pharmacol Exp Ther (2002) 1.19
Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J Neurochem (2010) 1.17
Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis (2005) 1.15
Catechol-O-methyltransferase gene polymorphism and chronic human pain: a systematic review and meta-analysis. Pharmacogenet Genomics (2012) 1.08
Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem Cell Biol (2008) 1.07
Resistance to salt-induced hypertension in catechol-O-methyltransferase-gene-disrupted mice. J Hypertens (2003) 1.01
Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug News Perspect (2007) 0.99
Distribution of catechol-O-methyltransferase (COMT) proteins and enzymatic activities in wild-type and soluble COMT deficient mice. J Neurochem (2010) 0.99
Transcriptional profiling of C57 and DBA strains of mice in the absence and presence of morphine. BMC Genomics (2007) 0.95
D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology (Berl) (2003) 0.92
Evolutionary relationships of the prolyl oligopeptidase family enzymes. Eur J Biochem (2004) 0.92
Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. J Comp Neurol (2008) 0.92
Are genetic variants of COMT associated with addiction? Pharmacogenet Genomics (2010) 0.92
Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp Neurol (2009) 0.91
Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease. Brain Behav (2013) 0.91
Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. Biochem Pharmacol (2002) 0.90
Catechol-O-methyltransferase and pain. Int Rev Neurobiol (2010) 0.90
The multiple faces of quercetin in neuroprotection. Expert Opin Drug Saf (2009) 0.89
Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors. J Histochem Cytochem (2012) 0.89
New prolyl oligopeptidase inhibitors developed from dicarboxylic acid bis(l-prolyl-pyrrolidine) amides. J Med Chem (2003) 0.87
Characterization of membrane-bound prolyl endopeptidase from brain. FEBS J (2008) 0.87
Distribution of immunoreactive prolyl oligopeptidase in human and rat brain. Neurochem Res (2007) 0.87
Intracerebroventricular antisense knockdown of G alpha i2 results in ciliary stasis and ventricular dilatation in the rat. BMC Neurosci (2007) 0.86
Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidase. Biochimie (2012) 0.86
Strong preferences of dopamine and l-dopa towards lipid head group: importance of lipid composition and implication for neurotransmitter metabolism. J Neurochem (2012) 0.85
Prolyl endopeptidase is involved in cellular signalling in human neuroblastoma SH-SY5Y cells. Neurosignals (2011) 0.85
Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats. Basic Clin Pharmacol Toxicol (2007) 0.85
Over-expression of a human chromosome 22q11.2 segment including TXNRD2, COMT and ARVCF developmentally affects incentive learning and working memory in mice. Hum Mol Genet (2009) 0.84
Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures. Brain Res (2008) 0.84
Different viabilities and toxicity types after 6-OHDA and Ara-C exposure evaluated by four assays in five cell lines. Toxicol In Vitro (2007) 0.84
Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. Biochem Pharmacol (2006) 0.84
Sequential expression, activity and nuclear localization of prolyl oligopeptidase protein in the developing rat brain. Dev Neurosci (2010) 0.83
Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther (2003) 0.83
The use of low-molecular-weight PEIs as gene carriers in the monkey fibroblastoma and rabbit smooth muscle cell cultures. J Gene Med (2002) 0.83
The role of PEI structure and size in the PEI/liposome-mediated synergism of gene transfection. Plasmid (2008) 0.83
Effect of genetic modifications in the synaptic dopamine clearance systems on addiction-like behaviour in mice. Basic Clin Pharmacol Toxicol (2010) 0.82
Four day inhibition of prolyl oligopeptidase causes significant changes in the peptidome of rat brain, liver and kidney. Biochimie (2012) 0.82
Different synergistic roles of small polyethylenimine and Dosper in gene delivery. J Control Release (2003) 0.82
High correlation between in vivo [123I]β-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in rats. EJNMMI Res (2013) 0.81
Agonists for neuropeptide Y receptors Y1 and Y5 stimulate different phases of feeding in guinea pigs. Br J Pharmacol (2003) 0.81
Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. Neuropharmacology (2011) 0.81
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis. J Neuroinflammation (2010) 0.81
Tissue histopathology, clinical chemistry and behaviour of adult Comt-gene-disrupted mice. J Appl Toxicol (2003) 0.81
Time-dependent protective and harmful effects of quercetin on 6-OHDA-induced toxicity in neuronal SH-SY5Y cells. Toxicology (2008) 0.80
Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study. J Clin Immunol (2012) 0.80
Hunting for peptide substrates of prolyl oligopeptidase: classical versus non-classical bioactive peptides. CNS Neurol Disord Drug Targets (2011) 0.80
Ara-C induces apoptosis in monkey fibroblast cells. Toxicol In Vitro (2003) 0.80
Increase in free choice oral ethanol self-administration in catechol-o-methyltransferase gene-disrupted male mice. Basic Clin Pharmacol Toxicol (2008) 0.80
Synergism in gene delivery by small PEIs and three different nonviral vectors. Int J Pharm (2004) 0.80
Constitutive Ret signaling is protective for dopaminergic cell bodies but not for axonal terminals. Neurobiol Aging (2009) 0.80
Deficient activity of mammalian prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease. Scand J Gastroenterol (2007) 0.80
Prolyl oligopeptidase: a rising star on the stage of neuroinflammation research. CNS Neurol Disord Drug Targets (2011) 0.80
Effect of cell-surface glycosaminoglycans on cationic carrier combined with low-MW PEI-mediated gene transfection. Int J Pharm (2004) 0.79
A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors. J Med Chem (2004) 0.79
Receptor subtypes Y1 and Y5 mediate neuropeptide Y induced feeding in the guinea-pig. Br J Pharmacol (2002) 0.79
Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum. Eur J Pharmacol (2003) 0.78
4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors. Bioorg Med Chem (2002) 0.78
Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice. Psychopharmacology (Berl) (2010) 0.78
Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors. Int Rev Neurobiol (2010) 0.78
Localization of prolyl oligopeptidase in the thalamic and cortical projection neurons: a retrograde neurotracing study in the rat brain. Neurosci Lett (2008) 0.78
Effect of forced chronic oral nicotine exposure on intravenous self-administration and rewarding properties of acute nicotine. Eur J Pharmacol (2008) 0.78
Alteration of prolyl oligopeptidase and activated α-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome. Biochem Pharmacol (2013) 0.78
Distribution and functions of catechol-O-methyltransferase proteins: do recent findings change the picture? Int Rev Neurobiol (2010) 0.78
Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions. Basic Clin Pharmacol Toxicol (2007) 0.78
Advanced brain dopamine transporter imaging in mice using small-animal SPECT/CT. EJNMMI Res (2012) 0.78
A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine. Toxicol In Vitro (2006) 0.78
Minocycline protects SH-SY5Y cells from 6-hydroxydopamine by inhibiting both caspase-dependent and -independent programmed cell death. J Neurosci Res (2011) 0.78
Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.78
Sex-dependent compensated oxidative stress in the mouse liver upon deletion of catechol O-methyltransferase. Biochem Pharmacol (2009) 0.78
Stress-induced analgesia and morphine responses are changed in catechol-O-methyltransferase-deficient male mice. Basic Clin Pharmacol Toxicol (2008) 0.77
Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells. Brain Res (2005) 0.77
Brain histamine and histamine H3 receptors following repeated L-histidine administration in rats. Life Sci (2003) 0.77
Dicarboxylic acid bis(L-prolyl-pyrrolidine) amides as prolyl oligopeptidase inhibitors. J Med Chem (2002) 0.77
The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. Eur J Pharm Sci (2005) 0.76
Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats. Basic Clin Pharmacol Toxicol (2007) 0.76
Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats. Eur J Pain (2011) 0.76
Different effects of scopolamine and inhibition of prolyl oligopeptidase on mnemonic and motility functions of young and 8- to 9-month-old rats in the radial-arm maze. Basic Clin Pharmacol Toxicol (2009) 0.75
Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion. Basic Clin Pharmacol Toxicol (2011) 0.75
Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site. Biochem J (2004) 0.75
COMT gene locus: new functional variants. Pain (2015) 0.75
Reduced natriuretic response to acute sodium loading in COMT gene deleted mice. BMC Physiol (2002) 0.75
Catechol-O-methyltransferase (COMT) protein expression and activity after dopaminergic and noradrenergic lesions of the rat brain. PLoS One (2013) 0.75